Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)-Reference-Cited by-同舟云学术

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

Published:2019-12-11 Issue:5 Volume:34 Page:1458-1461
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Rule Simon A.^ORCID,Cartron Guillaume,Fegan Christopher,Morschhauser Franck,Han Lingling,Mitra Siddhartha,Salles Gilles^ORCID,Dyer Martin J. S.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0658-7.pdf

Reference12 articles.

1. Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219–32.

2. Tucker D, Rule S. Novel agents in mantle cell lymphoma. Expert Rev Anticancer Ther. 2017;17:491–506.

3. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl J Med. 2013;369:507–16.

4. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib:updated safety and efficacy results. Blood. 2015;126:739–45.

5. Tucker DL, Rule SA. Ibrutinib for mantle cell lymphoma. Future Oncol. 2016;12:477–91.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma;eJHaem;2024-06-24

2. Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances;Leukemia & Lymphoma;2024-04-10

3. New Means and Challenges in the Targeting of BTK;Clinical Cancer Research;2024-04-05

4. SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-10

5. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies;International Journal of Hematology;2022-12-28